Jefferies Maintains a 'Buy' on Dynavax Technologies (DVAX); Broad Adult Label Should Be A Positive For Heplisav and Diabetes Opportunity
Tweet
Share
E-mailGet Alerts DVAX Hot Sheet
Price: $15.50 --0%
Rating Summary:
9 Buy, 1 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Rating Summary:
9 Buy, 1 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Join SI Premium – FREE
Jefferies maintains a 'Buy' on Dynavax Technologies (NASDAQ: DVAX) price target raised from $5 to $6.
Jefferies analyst says, "We are changing our model to assume a lucrative global partnership (with $75m upfront and 25% aggregate royalty rate) is signed by 4Q12 to commercialize Heplisav with a broader commercial reach. As a result, our US diabetes share for Heplisav increases from 37% to 52% in 2020, with WW revenues increasing from $339m to $418m. Separately, we are lowering our assumption for the effective royalty rate (from 25% to 15%) DVAX must pay to secure licenses to the broad patents covering hepatitis B surface antigen. As a result of the minor delay in filing Heplisav, we are assuming a later launch in mid-2013, but the delay is immaterial to our valuation. We see potential upside from a strong pharma partner’s reach to target a full diabetes population and further upside from a broader overall adult indication."
Jefferies raises FY11 EPS estimate from (0.47) to (0.44), lowers FY12 from (0.10) to (0.18), and raises FY13 from $0.39 to $0.80.
For an analyst ratings summary and ratings history on Dynavax Technologies click here. For more ratings news on Dynavax Technologies click here.
Shares of Dynavax Technologies closed at $4.08 yesterday.
Jefferies analyst says, "We are changing our model to assume a lucrative global partnership (with $75m upfront and 25% aggregate royalty rate) is signed by 4Q12 to commercialize Heplisav with a broader commercial reach. As a result, our US diabetes share for Heplisav increases from 37% to 52% in 2020, with WW revenues increasing from $339m to $418m. Separately, we are lowering our assumption for the effective royalty rate (from 25% to 15%) DVAX must pay to secure licenses to the broad patents covering hepatitis B surface antigen. As a result of the minor delay in filing Heplisav, we are assuming a later launch in mid-2013, but the delay is immaterial to our valuation. We see potential upside from a strong pharma partner’s reach to target a full diabetes population and further upside from a broader overall adult indication."
Jefferies raises FY11 EPS estimate from (0.47) to (0.44), lowers FY12 from (0.10) to (0.18), and raises FY13 from $0.39 to $0.80.
For an analyst ratings summary and ratings history on Dynavax Technologies click here. For more ratings news on Dynavax Technologies click here.
Shares of Dynavax Technologies closed at $4.08 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Science Applications (SAIC) PT Raised to $140 at Jefferies
- Ascendis Pharma (ASND) PT Raised to $312 at Oppenheimer
- Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
